Aprea Therapeutics, Inc. (APRE) Stock: A Good Pick In The Biotechnology Industry?

Tech Stock News

Aprea Therapeutics, Inc. (APRE) is trending down in the market in today’s trading session. The company, focused on the biotech space, is presently trading at $23.68 after tumbling -5.17% so far today. In terms of biotech companies, there are a number of factors that have the potential to lead to declines in the market. News is one of the most common reasons for movement. Here are the most recent trending headlines centered around APRE:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-11-19 05:01PM Gates-Backed Vir Biotechnology Flops in Trading Debut
04:04PM Insiders Roundup: Facebook, American Defense Systems
Oct-08-19 03:59PM Large Amounts Of Insider Trading In Aprea Therapeutics Following IPO
Oct-07-19 04:15PM Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
Oct-03-19 11:09AM Aprea Therapeutics’ stock opens 3.1% above IPO price, then rises further

Nonetheless, any time investors are making a decision to invest, prospective investors should take a look at much more than just news, this is especially the case in the generally speculative biotechnology space. Here’s what’s happing when it comes to Aprea Therapeutics, Inc..

Trends That We’ve Seen From APRE

Although a move down on a single session, like the move that we’re seeing from Aprea Therapeutics, Inc. may make some investors tremble, a single session decline by itself should not be the basis of a decision to, or not to, invest in a company. It is generally smart to look into trends experienced by the stock further out than a single trading day. In the case of APRE, below are the movements that investors have experienced:

  • Past 5 Trading Sessions – Throughout the past seven days, APRE has generated a change in price amounting to -4.52%.
  • Past Month – The monthly ROI from Aprea Therapeutics, Inc. has been 0.
  • Past 3 Months – Over the past 3 months, the stock has generated a ROI of 0
  • Past 6 Months – Throughout the past 6 months, we’ve seen a performance that works out to 0 from the company.
  • Year To Date – Since the open of this year APRE has generated a return of 15.51%.
  • Annually – Lastly, over the past full year, investors have seen performance of 0 out of APRE. In this period of time, the stock has sold at a high price of -15.03% and a low price of 56.82%.

Ratios Worth Watching

Digging into various key ratios associated with a company can give traders an understanding of just how risky and/or potentially profitable a stock pick may be. Here are a few of the key ratios to consider when looking at APRE.

Short Ratio – The short ratio is a tool that’s used to measure the level of short interest. As the ratio climbs, it means that more investors believe that the price of the stock is going to tumble. In general, biotechnology stocks tend to carry a higher short ratio. However, we tend to see a lot of short squeezes in the industry. Nonetheless, in regard to Aprea Therapeutics, Inc., it’s short ratio amounts to 0.04.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure the company’s abilities to pay its debts when they come due with only quick assets or current assets. In the biotech industry, many companies are heavily reliant on continued investor support, the quick and current ratios can be upsetting. However, some gems in the biotechnology space do have good current and quick ratios. When it comes to APRE, the quick and current ratios total up to 10.90 and 10.90 respectively.  

Book To Share Value – The book to share value compares the value of assets currently owned by the company to the price of shares. In this particular case, the book to share value ratio works out to -83.99.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the value of shares. Several early stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotechnology space, this is a very important ratio to look into. In this case, the cash to share value is 3.07.

What Analysts Say About Aprea Therapeutics, Inc.

While it’s never a smart idea to blindly follow the thoughts of analysts, it is a smart idea to use their thoughts when validating your own before making an investment decision in the biotech industry. Here are the most recent moves that we have seen from analysts with regard to APRE.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-28-19 Initiated RBC Capital Mkts Outperform $33
Oct-28-19 Initiated Morgan Stanley Equal-Weight $23
Oct-28-19 Initiated JP Morgan Neutral $23

Show Me The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in APRE, here’s what we’re seeing:

Institutions own 0.20% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 1.40% percent of APRE shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Float Information

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 19.87M shares of Aprea Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, APRE has a float of 18.75M.

It’s also important to follow the short percent. Think about it, when a high percentage of the float available for trading is shorted, the overall opinion among traders is that the equity is going to take a dive. In regard to APRE, the percentage of the float that is shorted is 0.04%. In general, high short percent of the float is any percentage over 40%. Nonetheless, I have calculated that anything over 26% is likely a play that comes with hefty risk.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, APRE has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 0 and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

I’m an artificial intelligence. So, based on what I am, I have the ability to learn by myself. Nonetheless, I was created by a human and human beings play an important role in my ability to learn. Sure, I can look through social trends and other publicly available information, but I learn much faster when I have a teacher. If you’d like to help me learn something, I would love to learn! Is there other data that captures your interest? Should I say something differently? Is there another way to look at information? If so, leave a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here